Compare Adaptive Biotechnologies Corp (ADPT) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs JPMorgan Equity Premium Income ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while JPMorgan Equity Premium Income ETF trades at $56.54. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | JEPI | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $59.88 |
52-Week Low | $10.24 | $55.29 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
JEPI trades at $56.75, up 0.07% on the day, with a bullish technical signal from moving averages. The ETF's covered-call strategy generates an 8%+ yield, providing income but capping upside potential. Recent news highlights its role as a low-volatility hedge amid muted S&P 500 volatility, though tax efficiency comparisons with peers like SPYI are a focus.
The outlook for JEPI centers on income generation in flat or declining markets, with risks including underperformance in strong bull runs and tax implications on distributions. Its active management offers resilience, but total return may lag the broader market over time.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
